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Immunotherapy is changing the treatment of non-small cell lung cancer (NSCLC). The 
PD-1 inhibitor nivolumab has demonstrated meaningful results in terms of efficacy with 
a good safety profile. The novel approach to treating NSCLC using immunotherapy still 
has unsolved questions and challenging issues. The main doubts regarding the optimal 
selection of the patient are the role of this drug in first line of treatment, the individ-
ualization of the correct methodology of radiologic assessment and efficacy analysis, 
the best management of immune-mediated adverse events, and how to overcome the 
immunoresistance. The aim of this review is to analyze literature data on nivolumab in 
lung cancer with a focus on critical aspects related to the drug in terms of safety, the use 
in clinical practice, and possible placement in the treatment algorithm.
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RATiONALe FOR iMMUNe CHeCKPOiNT iNHiBiTORS
Several clinical observations foresaw the promising results arising from the employment of immu-
notherapy in lung cancer. Indeed, the lungs are involved in many autoimmune disorders. In addition 
to hyperplasia of fibroblasts, diminished collagen breakdown and production of autoantibodies, the 
pathophysiology of pulmonary disease includes activation of T cells, B cells, and alveolar macrophages. 
Activated T cells produce cytokines, such as interleukin-4 and interleukin-10, which enhance fibro-
blasts proliferation. Furthermore, activated T cells produce an altered form of interferon gamma 
(IFNγ) with a reduced skill to inhibit fibroblasts proliferation (1). Moreover, spontaneous tumor 
regressions, not only in cutaneous melanoma (2) but also in lung cancer (3), have been described 
and confirm the involvement of immune system in cancer control.
At the beginning of the twentieth century, Paul Ehrlich first proposed the idea that transformed 
cells can elicit immune system to repress them (4). The discovery of rejection of transplanted 
tumors in mice and the existence of tumor-associated antigens (5) led then Burnet to propose the 
hypothesis of cancer immune surveillance (6) with the assumption that “tumour cells provoke an 
effective immunological reaction with regression of the tumor and no clinical hint of its existence” 
(6). However, immune surveillance is not sufficient to explain the occurrence and growth of cancer in 
immunocompetent individuals. Indeed, tumors acquire ability to resist to host’s immune system. The 
term “cancer immunoediting” has been proposed to explain this complex interaction between cancer 
and host and includes three phases: elimination, equilibrium, and escape. During elimination phase, 
tumor growth induces the release of inflammatory signals that activate cells of the innate immune 
system. These are natural killer (NK), NK T cells, γδ T cells, macrophages, and dendritic cells (DCs). 
They produce IFNγ, which has antiproliferative and apoptotic effect, and induce chemokines such 
as CXCL10, CXCL9, and CXCL11. These chemokines block angiogenesis and recruit more NK and 
macrophages that promote the maturation of DCs. DCs capture necrotic tumor cells, migrate to 
lymph nodes, and present tumor antigens (TAs) to naïve CD4+ T cells leading to their differentiation 
in effector CD4+ T cells, development of TA-specific CD8+ T cells, and their expansion. Finally, 
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TA-specific T cells can home to tumor site and eliminate tumor 
cells. Some tumor cells that withstand the elimination phase 
enter the equilibrium process. During this phase, activated T cells 
and IFNγ manage to limit tumor growth without removing it. 
Nevertheless, tumor cells with reduced immunogenicity for low 
levels of TAs survive and become resistant to immune system. 
They enter the escape phase and expand in an uncontrolled way 
(7). To become effector T cells, naïve T cells must recognize their 
specific TAs and interact with DCs through major histocompat-
ibility complex. This interaction involves both costimulatory and 
coinhibitory signals. In normal tissues, there is a balance between 
these signals. By contrast, inhibitory receptors and ligands are 
overexpressed on tumor cells and in tumor microenvironment. 
For example, high proportions of CD4+CD25+ T cells are present 
in the tumor-infiltrating lymphocytes (TILs) of patients with 
non-small cell lung cancer (NSCLC) (8). These T cells show high 
expression of CTLA-4 on their surface and inhibit the activation 
of T cells (9).
Immune checkpoints, such as CTLA4 and PD-1, are crucial 
to maintain the balance between costimulatory and inhibitory 
signals limiting excessive immune response against self-antigens. 
Thus, they are potential targets for cancer therapies.
CTLA4 is expressed on CD8+ T cells, CD4+ T cells, and on 
regulatory T cells (Treg) and is involved in early stages of T cell 
activation. Its ligands are CD80 (B7.1) and CD86 (B7.2) expressed 
on antigen-presenting cells (APCs) like DCs (10). CD28 is a 
costimulatory receptor also expressed on T cells, which binds to 
CD80 and CD86 with consequent activation of T cells. CTLA4 
interacts with CD80 and CD86 with higher affinity than CD28 
does and inhibits CD4+ T cell activation (11).
Even though CTLA4 is expressed by activated CD8+ effec-
tor T cells, the major physiological role of CTLA4 seems to be 
through distinct effects on the two major subsets of CD4+ T cells: 
downmodulation of helper T cell activity and enhancement of Treg 
activity. The latter is crucial for the maintenance of self-tolerance 
(12).
PD-1, as CTLA4, is expressed on T cells, but contrary to 
CTLA4, it is involved in the late phases of immune reactions 
and mostly within the tumor microenvironment. Its ligands are 
PD-L1 (B7-H1) and PD-L2 (B7-DC) that are expressed on APCs 
and tumor cells. The interaction of PD-1 with its ligands results in 
reduced effector T cell proliferation, exhaustion of T cell activity, 
and enhancement of Treg proliferation (13). Tumors are able to 
escape immune control because of upregulation of PD-1 on their 
surface. Indeed, PD-L1 is expressed in about 50% of NSCLC, 
mostly in squamous subtypes at advanced stage, and seems to 
correlate with poor prognosis (14, 15).
Two mechanisms of PD-1 ligands upregulation are present, 
known as innate immune resistance and adaptive immune 
resistance. The first refers to the constitutive expression of PD-L1 
through involvement of oncogenic signaling pathways, such as 
AKT and STAT3, as in ALK-positive lung cancer (16, 17). In 
adaptive immune resistance, PD-1 ligands are overexpressed on 
tumor cells in response to cytokines, in particular IFNγ (18). The 
adaptive immune resistance is probably involved in most NSCLC 
without an oncogenic driver. Indeed, higher neoantigen burden 
seems associated with clinical benefit of PD-1 blockade (19).
Due to strong rationale and promising preclinical data, mono-
clonal antibodies anti-CTLA4 and anti-PD-1/PD-L1 have been 
extensively studied in advanced NSCLC. The therapeutic inter-
ference of immune synapse was a strategy adopted in preclinical 
model from 2010, and nivolumab was the “first in class” MoAb to 
be employed in clinical trials in advanced NSCLC immediately 
the unripe experience of Ab anti-CTLA4.
NivOLUMAB DeveLOPMeNT iN CLiNiCAL 
PRACTiCe: STATe OF THe ART
Nivolumab was evaluated in the Phase Ib dose-escalation trial 
Checkmate 003 (20) (Table 1) in 129 heavily pretreated NSCLC 
patients. It was administered at 1, 3, and 10  mg/kg i.v. every 
2 weeks for up to 96 weeks. Median OS for 3 mg/kg cohort was 
longer than mOS for 1 and 10 mg/kg (14.9 vs. 9.2 months). Median 
progression-free survival (mPFS) was 2.3  months, median 
duration of response was 17.0 months, and the overall response 
rate (ORR) was 17%, similar for squamous and non-squamous 
NSCLC. Eighteen patients discontinued the study without pro-
gression and 50% of these continued to respond 9 months after 
the last dose. The dose of 3 mg/kg every 2 weeks of nivolumab was 
determined as the dose to be employed in further trials.
CheckMate 063 (21) (Table  1), a Phase II, single-arm trial, 
evaluated nivolumab activity in 117 pretreated advanced squa-
mous NSCLC patients. ORR was the primary endpoint. About 
14.6% (17/117) of patients obtained a response, 26% (30/117) had 
stable disease (SD). Response was achieved in a median time of 
3.3 months, and the majority of responses were ongoing at the 
time of the report. Patients with SD had a duration of response 
of 6  months. Nivolumab demonstrated activity irrespective of 
PD-L1 expression, using a cutoff of 5%. PD-L1 was assessed in 
76 patients, 33% (25/76) had PD-L1 expression and among them 
6 patients had a partial response, whereas 7 patients of 51 with 
PD-L1-negative obtained a response.
After these promising results, nivolumab was compared with 
chemotherapy in two randomized Phase III trials in second line 
in advanced squamous and non-squamous NSCLC.
CheckMate 017 (22) (Table 1), a randomized open-label Phase 
III trial, employed nivolumab or docetaxel in advanced squamous 
(SCC) NSCLC after progression to first-line chemotherapy. OS 
was the primary endpoint, and it was significantly longer in the 
nivolumab arm compared to docetaxel (9.3 vs. 6.0  months). 
Nivolumab decreased the risk of death of 41% (hazard ratio 0.59; 
95% CI, 0.44–0.79; P <  0.001). In the experimental arm, ORR 
(20 vs. 9%) and PFS (3.5 vs. 2.8 months; hazard ratio for death 
or disease progression, 0.62; 95% CI 0.47–0.81; P < 0.001) were 
also increased.
There was no correlation between PD-L1 expression 
and nivolumab activity (PD-L1 analysis was performed 
retrospectively).
Nivolumab was also compared to docetaxel in the 
CheckMate 057 (23) (Table 1), a randomized Phase III trial in 
non-squamous advanced NSCLC after platinum-based doublet 
chemotherapy (PT-DC). OS was the primary endpoint, and as 
previously seen in SCC, it was improved for nivolumab-treated 
TABLe 1 | Major clinical trials of nivolumab in lung cancer.
Trial No. 
patients
Phase Histology Setting Treatment Outcome Safety Notes
CheckMate 
003 (20)
129 Phase I Non-small cell 
lung cancer 
(NSCLC)
Pretreated Nivolumab dose 
escalation
OS 3 mg/kg 
14.9 months vs. 
mOS 1 and 10 mg/kg 
9.2 months
3 treatment-related deaths (associated with pneumonitis)
CheckMate 
063 (21)
117 Phase II Squamous 
NSCLC
Pretreated Nivolumab 3 mg/kg OS 8.2 months 1-year 
OS 41%
17% of the pts reported Grade 3 or 4 treatment-related AEs. 
Two treatment-associated deaths (pneumonia and ischemic 
stroke)
PD-L1 cutoff of 5%; 
nivolumab demonstrated 
activity irrespective of 
PD-L1 expression
CheckMate 
017 (22)
272 Phase III Squamous 
NSCLC
Pretreated Nivolumab vs. docetaxel OS 9.3 vs. 6.0 months Grade 3 or 4 treatment related were reported in 7% of the 
pts in the nivolumab arm vs. 55% in the docetaxel arm
Nivolumab demonstrated 
activity irrespective of 
PD-L1 expression
CheckMate 
057 (23)
582 Phase III Non-
squamous 
NSCLC
Pretreated Nivolumab vs. docetaxel OS 12.2 vs. 
9.4 months
Grade 3 or 4 treatment-related AEs were reported in 10% 
of the pts in the nivolumab arm vs. 54% in the docetaxel arm
PD-L1 cutoff ≥1, ≥5, and 
≥10%; relevant predictive 
association between OS, 
median progression-free 
survival, overall response 
rate (ORR), and PD-L1 
expression
CheckMate 
012 (24)
52 Phase I NSCLC I line Nivolumab 3 mg/kg OS 19.4 months 
12-month OS 73%
19% of pts reported Grades 3–4 treatment-related AEs; 
12% discontinued because of a treatment-related AE
PD-L1 cutoff ≥1 and <1%, 
≥5 and <5%; clinical 
activity regardless of PD-L1 
expression, but higher 
ORR for greater PD-L1 
expression. Not clear 
correlation between PFS, 
OS, and PD-L1 expression
CheckMate 
012 (25)
56 Phase I NSCLC I line Nivolumab + platinum-
based doublet 
chemotherapy (PT-DC)
OS PT-DC + Nivo 
10 mg/kg from 11.6 to 
19.2 months; plus Nivo 
5 mg/kg not reached
45% of pts reported Grade 3 or 4 treatment-related AEs. 
21% of pts discontinued because of a treatment-related AEs
Nivolumab demonstrated 
activity irrespective of 
PD-L1 expression
CheckMate 
032 (26)
216 Phase I/II Small cell lung 
cancer
Pretreated Nivolumab or 
sequentially cohorts 
nivolumab + ipilimumab
OS Nivo 4.4 months; 
OS Nivo + IPI 
6–7.7 months; 1-year 
OS 33 and 35–43%
Grade 3 or 4 treatment-related AEs events occurred in 
13% of pts in the nivolumab 3 mg/kg cohort, 30% in the 
nivolumab 1 mg/kg + ipilimumab 3 mg/kg, and 19% in the 
nivolumab 3 mg/kg + ipilimumab 1 mg/kg. Two pts who 
received nivolumab 1 mg/kg + ipilimumab 3 mg/kg died 
from treatment-related AEs (myasthenia gravis and renal 
failure); 1 who received nivolumab 3 mg/kg + ipilimumab 
1 mg/kg died from treatment-related pneumonitis
No correlation between 
PD-L1 expression and 
response
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patients (12.2 vs. 9.4 months, hazard ratio for death, 0.73; 96% 
CI, 0.59–0.89; P = 0.002). OS rate at 1 year and 18 months was 
longer for the experimental arm (51 and 39% vs. 39 and 23%) in 
addition, there was an advantage also for ORR (19 vs. 12%) with 
a longer duration of response and a median time to response of 
2.1 vs. 2.6 months. Immunotherapy was not superior to chemo-
therapy in terms of mPFS (2.3 and 4.2 months). PD-L1 expres-
sion was assessed retrospectively on archival or recent tumor 
tissue. PD-L1 cutoff was ≥1, ≥5, and ≥10%. It was observed 
a relevant predictive association among OS, mPFS, ORR, and 
PD-L1 expression. Subgroup analysis revealed that patients 
who received third line of chemotherapy, the presence of central 
nervous system metastases, EGFR mutation, and patients who 
lived in South America, Asia, and Australia obtained more ben-
efits from chemotherapy. Kaplan–Meyer curves of OS and PFS 
revealed a chemotherapy early advantage, however, later curves 
crossed showing a nivolumab advantage. This unexpected find-
ing may be explained by an initial benefit from chemotherapy 
in patients who do not expressed PD-L1 but presented EGFR 
mutations. In fact, in this setting, the experimental drug pro-
vided less advantage respect to chemotherapy By contrast, in 
CheckMate 017 trial, Kaplan–Meyer curves had an early separa-
tion, particularly for OS. It can be related to nivolumab benefit 
in overall squamous NSCLC population.
CheckMate 012 trial (24, 25) (Table  1) was conducted in I 
line in advanced NSCLC. It is a Phase I multicohort study that 
evaluated the safety and efficacy of nivolumab monotherapy 
or combined to PT-DC. Pretreatment tissue was used only for 
biomarker evaluation and not for patients’ selection. In mono-
therapy, nivolumab was administered to 52 patients. ORR was 
23%, 27% of patients had SD with a disease control rate of 50%. 
mOS in overall population was of 19.4 months (16.8 months in 
squamous histology and NR in non-squamous), 12-month OS 
rate in overall population was 73% (76% in squamous histology 
and 72% in non-squamous), and 18-month OS rate in overall 
population was 57% (42% in squamous histology and 63% in 
non-squamous). In overall population, mPFS was 3.6 months and 
24-week PFS was 41%.
Clinical activity was observed regardless of PD-L1 expres-
sion, and higher ORR was related to greater PD-L1 expression. 
The correlation between PFS, OS, and PD-L1 expression is 
not clear. Smoking history seems to be associated with higher 
activity of nivolumab. In the combination arm, nivolumab was 
administered to 56 patients for four cycles every 3  weeks at 
10 mg/kg +  cisplatin–gemcitabine in squamous histology, plus 
cisplatin–pemetrexed in non-squamous histology or at dose of 
5 or 10 mg/kg + carboplatin–paclitaxel in all histologies. After 
the planned chemotherapy cycles, patients received nivolumab 
alone. Nivolumab dose of 5 mg/kg was emended when trial was 
ongoing. mPFS ranged from 4.8 to 7.1 months, 24-week PFS rate 
from 38 to 71%. Range of mOS of PT-DC + nivolumab at 10 mg/
mg was from 11.6 to 19.2  months, but it was not reached for 
nivolumab at 5 mg/kg +  carboplatin–paclitaxel. ORR was 48% 
for patients with PD-L1 expression >1 and 43% if PD-L1 was 
<1%. Nivolumab activity also occurred if PD-L1 was absent or 
low expressed, whereas smoking history was related to higher 
clinical activity.
Small cell lung cancer (SCLC) is strongly related to tobacco 
use, and as a result, it is characterized by high mutational burden. 
Response to second-line chemotherapy is around 9–23% depend-
ing on platinum sensitivity.
CheckMate 032 (26) (Table  1) is a muticentre, Phase I/
II open-label trial. Patients affected by limited or extended 
SCLC, after at least platinum-based chemotherapy, received: 
nivolumab 3  mg/kg every 2  weeks, nivolumab +  ipilimumab 
every 3 weeks for four cycles (1 + 1, 1 + 3, and 3 + 1 mg/kg), 
then nivolumab 3 mg/kg every 2 weeks. Patients were enrolled 
sequentially in the four cohorts. The cohort nivolumab 1 mg/
kg +  ipilimumab 1  mg/kg is the smaller with only 3 patients 
of 216 overall patients. At interim analysis, ORR was 10% for 
nivolumab, 23% for nivolumab 1 mg/kg + ipilimumab 3 mg/kg, 
and 19% for nivolumab 3 mg/kg + ipilimumab 1 mg/kg. mOS 
was 4.4 months for nivolumab, 7.7 months for nivolumab 1 mg/
kg + ipilimumab 3 mg/kg, and 6.0 months for nivolumab 3 mg/
kg +  ipilimumab 1  mg/kg. One-year overall survival was 33, 
43, and 35%. mPFS was 1.4, 2.6, and 1.4 months. Most frequent 
Grade 3 or 4 AEs were diarrhea and increase of lipase occur-
ring in 4, 30, and 15%. PD-L1 was evaluated retrospectively on 
archival or fresh tissue collected. PD-L1 expression in SCLC was 
lower compared to NSCLC, and there was no correlation found 
between PD-L1 and response.
This trial evidenced similar responses between platinum-
resistance and platinum-sensitive patients. The reason is probably 
due to the mechanism of action of immune checkpoint that is 
completely different from chemotherapy (i.e., topotecan), and it 
works better in presence of high mutational burden. No differ-
ences were found between patients pretreated with one or more 
line of chemotherapy. Unfortunately, the absence of randomiza-
tion does not allow to a comparison between the different arms. 
Nivolumab achieves rapid and durable responses. The majority of 
nivolumab studies are limited by the evaluation of PD-L1 expres-
sion that can change over time, so tissue collection deriving from 
archival or recent biopsy does not offer a PD-L1 real status even 
if this point remains a major concern to debate.
Trials of immune checkpoint inhibitors used different test to 
establish PD-L1 expression, so there is no unique test for PD-L1 
evaluation and a comparison among PD-1/PD-L1 inhibitors is 
not possible. For this reason, the Blueprint development group 
has proposed a way to compare different diagnostic assays for 
future clinical practice that requires validation.
Interesting future development of nivolumab (Table  2) in 
lung cancer are as adjuvant therapy (NCT02595944), after 
chemo-radiotherapy (NCT02768558), in association with RT in 
case of intracranial metastasis (NCT 02696993), as maintenance 
treatment (NCT02538666; NCT02713867), and in combina-
tion with ipilimumab/chemotherapy/TKIs (NCT02477826, 
NCT02785952, NCT02659059, NCT02154490, NCT02041533, 
NCT02613507, NCT02481830, and NCT02864251).
NivOLUMAB – SAFeTY PROFiLe
As mentioned earlier, nivolumab demonstrated an improvement 
over current available therapies with a risk profile acceptable 
relative to the clinical benefit offered.
TABLe 2 | Selected future development of nivolumab in lung cancer.
Trial Phase Histology Setting Treatment Status Association
CheckMate 227 NCT02477826 Phase 
III
Non-small 
cell lung 
cancer 
(NSCLC)
I line Nivo, NIvo + IPI, Nivo + platinum-
based doublet chemotherapy 
(PT-DC), PT-DC
Recruiting CT and 
Immunotherapy
ANVIL NCT02595944 Phase 
III
NSCLC IB–IIIA adjuvant Nivo Recruiting Immunotherapy
Lung-MAP NCT02785952 Phase 
III
Squamous 
NSCLC
II line Nivo, Nivo + IPI Recruiting Immunotherapy
CheckMate 451 NCT02538666 Phase 
III
ED-small 
cell lung 
cancer 
(SCLC)
Maintenance after I line CT Nivo + Placebo, Nivo + Ipilimumab Recruiting Immunotherapy
CheckMate-026 NCT02041533 Phase 
III
NSCLC 
PD-L1+
I line Nivo, investigator’s choice CT Active, not 
recruiting
CT and 
Immunotherapy
Cisplatin and etoposide + RT followed 
by Nivo/placebo for locally advanced 
NSCLC NCT02768558
Phase 
III
NSCLC Unresectable, medically 
inoperable disease, or 
patients who refuse resection 
stage IIIA or stage IIIB disease
Thoracic RT, cisplatin, 
etoposide ± Nivo
Not yet 
recruiting
RT, CT, and 
Immunotherapy
CheckMate 078 NCT02613507 Phase 
III
NSCLC II line, after platinum-based CT Nivo, docetaxel Recruiting CT and 
Immunotherapy
Phase I/II trial of nivolumab with radiation 
or nivolumab and ipilimumab with 
radiation for the treatment of intracranial 
metastases from NSCLC NCT02696993
Phase 
I/II
NSCLC Stage IV metastatic disease 
with intracranial disease
Nivo + IPI + WBRT, 
Nivo + IPI + SRS
Not yet 
recruiting
RT and 
Immunotherapy
CheckMate 331 NCT02481830 Phase 
III
SCLC II line, after platinum-based CT Nivolumab, topotecan, amrubicin Not yet 
recruiting
CT and 
Immunotherapy
CheckMate 384 NCT02713867 Phase 
III
NSCLC Nivo 240 mg every 2 W vs. 
Nivo 480 mg every 4 W after 
up to 12 months of Nivo at 
3 mg/kg or 240 mg every 2 W
Nivo 240 mg every 2 W vs. 
nivolumab 480 mg
Recruiting Immunotherapy
CheckMate 568 NCT02659059 Phase II NSCLC I line Nivo + IPI Recruiting Immunotherapy
Lung-MAP NCT02154490 Phase 
II/III
Squamous 
NSCLC
II line Docetaxel, durvalumab, erlotinib, 
hydrochloride, FGFR, AZD4547, 
IPI, laboratory biomarker analysis, 
Nivo, palbociclib, rilotumumab, 
taselisib
Recruiting Immunotherapy, 
CT, and target 
therapy
CheckMate 722 NCT02864251 Phase 
III
NSCLC 
EGFR mut, 
T790M
After 1 line EGFR TKI therapy Nivo + IPO vs. 
Nivo + PEM + CDDP/CBDCA
Not yet 
recruiting
Immunotherapy, 
CT, and target 
therapy
CT, chemotherapy; Nivo, nivolumab; IPI, ipilimumab; PEM, pemetrexed; W, week.
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Phase i
In Phase I study of nivolumab, treatment-related select adverse 
events of any grade were observed in 41% of 129 patients with 
NSCLC, and the most common included skin, gastrointestinal, 
and pulmonary events (16, 12, and 7%, respectively). Grades 
3–4 treatment-related adverse events occurred in 14% of cases, 
with fatigue (3.1%) and pneumonitis (2.3%) being the most 
common. There were three treatment-related deaths associ-
ated with pneumonitis. No clear relationships between the 
occurrence of pneumonitis and dose level or treatment dura-
tion were noted (20).
Phase ii
In the non-comparative Phase II trial (ONO-4536-06) conducted 
in Japanese population (currently not published), any grade 
drug-related adverse events were reported in 68% of patients. 
Decrease appetite, malaise, pyrexia, and rash were the most 
frequent toxicities. Grade 3/4 toxicities were experienced in 
6Cortinovis et al. Nivolumab in Lung Cancer
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5.7%. Regarding the immune-related adverse events, the most 
common was skin rash (reported in 28% of patients), followed 
by endocrine (11.4%), pulmonary, gastrointestinal, infusion 
reactions (each occurring at 5.7%), and renal (2.9) toxicity. No 
Grade 3/4 toxicities occurred (27).
CheckMate 063: SCC
In the Phase II, single-arm study CA209063 (CM063), any grade 
treatment-related adverse events were reported in 74% of patients 
and included fatigue (33%), decreased appetite (19%), nausea 
(15%), asthenia (12%), rash (11%), and diarrhea (10%). Grades 
3–4 treatment-related adverse events were observed in 17% of 
subjects, with fatigue (4%), pneumonitis (3%), and diarrhea 
(3%) being the most frequent. Treatment-related adverse events 
led to discontinuation of the drug in 12% of patients. Immune-
mediated adverse reactions, defined as cases requiring use of 
systemic corticosteroids with no clear alternative cause were 
immune-mediated pneumonitis (6.0%), hypothyroidism (4.3%), 
hyperthyroidism (1.7%), motor dysfunction (1.7%), rash (1.7%), 
adrenal insufficiency (0.9%), vasculitis (0.9%), colitis (0.9%), and 
renal dysfunction (0.9%). These immunological side effects were 
treated with administration of high-dose corticosteroids followed 
by a taper and interruption of nivolumab therapy. Of note, no 
patients were rechallenged with nivolumab following corticoster-
oid taper. Finally, two treatment-associated deaths (one due to 
pneumonia and one due to stroke) occurred (21).
CheckMate 017
In the Phase III open-label randomized trial CheckMate 017 
comparing nivolumab vs. docetaxel in SCC NSCLC, the inci-
dence of adverse events was 58% in the nivolumab group vs. 
86% in the docetaxel arm. The most frequent adverse events in 
patients treated with nivolumab were fatigue (16%), reduced 
appetite (11%), and asthenia (10%), whereas in patients treated 
with docetaxel, neutropenia (33%), fatigue (33%), alopecia 
(22%), and nausea (23%) were commonly observed. In the overall 
study population, treatment-related Grade 3/4 adverse events 
were more common with docetaxel (55%) with a high number 
of hematologic toxic events and infections. On the contrary, 
only 6.9% of patients in the nivolumab arm reported Grade 3/4 
treatment-related adverse events, and they were commonly rep-
resented by fatigue, decreased appetite, and leukopenia. Overall, 
3.1% of patients in the nivolumab arm discontinued treatment due 
to an AE compared with 10.1% for docetaxel. The most frequently 
reported (≥3% of patients) selected treatment-related AEs of any 
grade were hypothyroidism (4 vs. 0%), diarrhea (8 vs. 20%), and 
pneumonitis (5 vs. 0%) for nivolumab and docetaxel, respectively. 
Discontinuation due to toxicity issues occurred in 10% of patients 
on docetaxel, mostly due to peripheral neuropathy, while only 
3% interrupted nivolumab mainly for pneumonitis. Finally, no 
treatment-related deaths were reported for patients treated with 
nivolumab, whereas three deaths occurred (one death each from 
interstitial lung disease, pulmonary hemorrhage, and sepsis) in 
docetaxel arm (22).
Data regarding longer follow-up of the study showed no 
unpredicted adverse events with nivolumab and a good safety 
profile compared to docetaxel (28).
CheckMate 057: nsq NSCLC
In the Phase III CheckMate 057 having similar characteristics 
in terms of design, endpoints, drugs, and schedules of treatment 
of CheckMate 017, but with a larger samples (in the CheckMate 
057:292 and 290 patients in the nivolumab and docetaxel arm, 
respectively, in the CheckMate 017:135 patients in the nivolumab 
arm and 137 in the docetaxel arm), the safety profile was in line 
with the previous reports. More in details, safety analysis demon-
strated that AEs of any grade occurred in 69% of patients receiving 
nivolumab and 88% of patients receiving docetaxel. Among them, 
the most frequent were fatigue, nausea, decreased appetite, and 
asthenia in the nivolumab group, whereas neutropenia, fatigue, 
nausea, alopecia, diarrhea, and anemia were the most common in 
the docetaxel group. Treatment-related Grade 3/4 adverse events 
were reported by 10% of the patients treated with nivolumab, 
with fatigue, nausea, and diarrhea being the most common and 
each reported in 1% of subjects. In comparison, 54% of patients 
in the docetaxel group experienced mainly neutropenia (27% of 
cases), febrile neutropenia (10%), leukopenia (8%), fatigue (5%), 
and anemia (3%). Treatment-related select adverse events of any 
grade reported in ≥2.5% of patients were rash (9% of patients vs. 
3%, respectively, in the nivolumab and docetaxel arm), pruritus 
(8 vs. 1%), erythema (1 vs. 4%), diarrhea (8 vs. 23%), hypothy-
roidism (7 vs. 0%), increased alanine aminotransferase levels (3 
vs. 1%), increased aspartate aminotransferase (AST) levels (3 vs. 
1%), infusion-related reactions (3 vs. 3%), and pneumonitis (3 
vs. 0.4%). Grades 3–4 treatment-related select adverse events 
experienced in patients receiving nivolumab were pneumonitis 
(1.0% of patients), diarrhea and increased γ-glutamyl transferase 
levels (each reported in 0.7% of cases) and rash, dermatitis, colitis, 
increased AST levels, transaminases increased and interstitial 
lung disease (each reported in 0.3% of patients). Treatment dis-
continuation due to adverse events occurred in 5% of patients 
receiving nivolumab (mainly because of pneumonitis) and in 15% 
of subjects treated with docetaxel (mostly because of fatigue) (23).
CheckMate 012: I Line
Recently, the results of the first-line monotherapy with nivolumab 
for advanced NSCLC in the Phase I, multicohort, CheckMate 
012 trial were published. Also in this setting, nivolumab was well 
tolerated, with 19% of patients reporting Grades 3–4 treatment-
related AEs and no treatment-related deaths. According to prior 
nivolumab data (20–23, 27), treatment-related select AEs affected 
the skin (any grade, 25%; Grades 3–4, 4%), endocrine (any grade, 
14%; Grades 3–4, 0%), gastrointestinal (any grade, 12%; Grades 
3–4, 2%), and pulmonary organ (any grade, 6%; Grades 3–4, 2%) 
(24). These toxicities were easily manageable using established 
guidelines.
Recently, the results of the cohort of the CheckMate 012 study 
investigating nivolumab + PT-DC in first-line advanced NSCLC 
were published. A total of 56 patients were enrolled and treated 
with the following regimens: nivolumab 10  mg/kg +  gemcit-
abine–cisplatin (squamous) or pemetrexed–cisplatin (non-
squamous), or nivolumab 5 or 10 mg/kg + paclitaxel–carboplatin 
(all histologies). No dose-limiting toxicities occurred during the 
first 6  weeks of treatment. In patients treated with nivolumab 
TABLe 3 | Management of selected immune-related adverse events.
Organ (disorder) Grade 1–Grade 2 Grade 3–Grade 4
Gastrointestinal 
(diarrhea colitis)
Supportive care measures Withheld the drug
Loperamide Steroids at 1–2 mg/kg prednisolone or IV equivalent
If no improvement in 5 days, or if worsening of symptoms, 
commence steroids at a dose of 0.5–1 mg/kg/day of 
prednisolone (or IV equivalent)
If no improvement consider infliximab 5 mg/kg
Grade 4: permanent discontinuation of drug
Dermatologic (diffuse, 
maculopapular rash)
Manage symptomatically Grade 3: the drug should be withheld for one dose
If persistent Grade 2, the drug should be withheld for one dose Grade 4: permanent discontinuation of drug
Hepatic (elevation in 
liver function tests)
High-dose IV glucocorticosteroids for 24–48 h, followed by an 
oral steroid taper (dexamethasone or prednisone)
Grade 3/4: permanent discontinuation of the drug
Lung (pneumonitis) Observation Discontinue drug administration
Delay drug administration High-dose steroids with methylprednisolone (e.g., 1 g/day IV)
Consider steroids (e.g., prednisone 1 mg/kg/day PO or 
methylprednisolone 1 mg/kg/day IV)
Add prophylactic antibiotics
If not improving after 48 h or worsening, administer additional 
immunosuppressive therapy (e.g., infliximab, mycophenolate, and 
immunoglobulins). If improving, taper steroids
Discontinue treatment permanently
Endocrine (hypophysitis) Asymptomatic, no intervention needed: monitor only Withhold the treatment
Use methylprednisolone 1–2 mg/kg intravenously (IV). This should be 
followed by prednisone 1–2 mg/kg orally (PO) once daily with gradual 
tapering over 4 weeks and replacement hormones during the tapering. 
The drug can be restarted with Grade 2, but Grade 3/4 endocrinopathy 
requires permanent drug discontinuation
Renal injury Monitor renal function, promote hydration and cessation of 
nephrotoxic drugs
Prednisolone 1–2 mg/kg or IV equivalent. Discontinue the drug
Nephritis Consider prednisolone 0.5–1 mg/kg
Adapted from Ref. (35, 36).
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full dose + PT-DC, treatment-related AEs of any grade occurred 
in 93% of patients, whereas Grade 3/4 AEs occurred in 50% 
of patients. In the overall population, 95 and 45% of patients 
experienced any Grade and Grade 3 or 4 treatment-related AEs, 
respectively. The most frequent (≥30% of patients) treatment-
related AEs of any grade were fatigue, nausea, decreased appetite, 
and alopecia. Regarding treatment-related Grade 3 or 4 AEs, they 
were mainly (≥5% of patients) pneumonitis, fatigue, and acute 
renal failure. The majority of patients experienced a treatment-
related select AE during the combination period than during 
nivolumab monotherapy. Treatment-related AEs led to discon-
tinuation of all study therapy in 21% of patients and Grade 3 or 4 
treatment-related AEs led to discontinuation in 14% of patients. 
However, no treatment-related deaths were reported. Because of 
the high percentage of discontinuation due to AEs, the potential 
regimen for future indication could be the nivolumab 5  mg/
kg + paclitaxel–carboplatin (25).
Recently, the results from CheckMate 026 were presented. The 
study was one of the first trial in chemotherapy-naïve patients 
with stage IV or recurrent NSCLC to compare nivolumab with 
a platinum-based regimen. A total of 541 patients received 
nivolumab 3  mg/kg every 2  weeks or investigator’s choice of 
PT-DC every 3 weeks for up to six cycles. Despite an enriched 
population with PD-L1-positive tumors (threshold defined as 
≥1%; n = 423), nivolumab did not show superior mPFS compared 
with chemotherapy (4.2 vs. 5.9 months; HR 1.15, P = 0.25) (29).
In this context, the CheckMate 227 Phase III open-label 
study evaluating platinum-based chemotherapy alone or in 
combination with nivolumab +  ipilimumab or nivolumab in 
previously untreated advanced NSCLC (NCT02477826) is 
largely awaited.
A Toxicity Profile Never Seen Before
As mentioned, the introduction of immunotherapy in clinical trials 
showed a specific toxicity profile that is peculiar from the known 
side effects of cytotoxic chemotherapy or targeted therapies (30). 
As a result, some patients experienced a novel type of AE consid-
ered to be linked to an immune-mediated response directed to 
different tissues: an immume-related AE (irAE). The percentage 
of the incidence is around 9%, and the most common irAEs are 
skin rash, hypothyroidism, diarrhea and colitis, pneumonitis, and 
increased hepatic function test. These side effects are generally 
manageable but can be fatal in some cases (31–34). Moreover, 
their appearance may be subclinical and early diagnosis and 
management could be extremely challenging. For these reasons, 
it is important to underline the need to act a careful monitoring 
of patients receiving nivolumab in order to offer a prompt and 
optimal management of irAEs. For this reason, physicians should 
be aware about the use of the established safety guidelines (20, 
23, 35, 36). In addition, education of patients and caregivers on 
recognition of irAEs has a relevant role. Finally, input from other 
specialties may be valuable for difficult cases (Table 3).
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Peculiar Aspects
Combination
The combination of nivolumab with different drugs in NSCLC 
is under investigation. Of note, combinations of the anti-CTLA4 
antibody ipilimumab + nivolumab have showed promising results 
(37), and several trials are ongoing (NCT02477826, NCT02659059, 
NCT02864251, NCT01454102, and NCT02869789). Toxicity 
management is a challenging issue, and new dosages and sched-
ules are under evaluation.
Onset
The onset of immune adverse events occurs on average 6–12 weeks 
after starting of therapy. It should be considered that these events 
can happen within days of the first dose, after several months of 
treatment, and even after discontinuation of therapy.
Open Questions
Currently, many questions are still unsolved. First, the toxicity 
profile in “real-world,” since patients included in clinical trials 
do not represent the total population in clinical practice. In this 
setting, there is a lack of data as well as people with pre-existing 
autoimmune conditions. In such cases, physicians have to con-
sider if benefit exceeds the risk.
A number of case reports about rare irAEs are publishing in 
literature demonstrating the need to improve the recognition of 
clinical abnormalities and their association with nivolumab treat-
ment. The awareness of nivolumab safety will grow as experience 
of physician will increase as well.
Second, immunotherapy has improved survival and as a 
consequence, a new set of survivorship issues may arise for 
management. For instance, there may also be sequelae due to 
an interplay between late effects of radiotherapy in addition to 
immunotherapy and association among immunotherapeutics 
MoAbs or targeted therapies must be deeply explored in order to 
unveil newer and unexpected safety concerns.
NivOLUMAB ON ReAL-wORLD 
POPULATiON: THe STReNGTHS  
AND weAKNeSSeS
After the unprecedented clinical results regarding the activity 
and the long-term response duration even in heavily pretreated 
NSCLC squamous and non-squamous subtypes, nivolumab 
quickly became an undebatable gold standard in second-line 
setting. These results are noteworthy also because adverse events 
are generally manageable and or reversible.
The strength of nivolumab arose from clinical trials, especially 
those well-designed Phase III (22, 23). In order to maximize these 
astonishing results in real-world population, it is necessary to 
understand in which patients this drug must be employed and in 
which nivolumab does not work at all. In addition, it is important 
to highlight the challenging “gray zones” coming from nivolumab 
experience in the past 2 years of clinical practice.
In squamous and in non-squamous patients, nivolumab shows 
nearly 20% of RR and approximately two-third of response are 
durable and persisting with a plateau after more than 24 months 
of follow-up in overall survival. As a consequence, it has been 
demonstrated that nivolumab can provide a real control of 
the disease leading to the concept of disease chronicization. 
Unfortunately, 80% of patients have a temporary control of the 
disease, and in the era of precision medicine, it is essential to 
understand the main reasons. Looking at the cross-over shape 
of the CheckMate 057 (23) overall survival curves between doc-
etaxel and nivolumab, the main reason for this particular aspect 
can be due to the activity of the immune checkpoint inhibitor 
in one undefined subpopulation. This point led investigators to 
analyze one or more predictive biomarkers, and as a result, PD-L1 
tumoral staining has became an important putative biomarker 
to select the patient who would benefit more with of this class of 
drugs (38).
Nivolumab has been studied in all-comers patients, regardless 
of PD-L1 expression; however, a post hoc analysis analyzing the 
percentage of positivity of tumoral PD-L1 was carried out and 
different cutoff (>1, >5, and >10%) were reported.
In non-squamous histotype, the PD-L1 tumor expression is 
predictive of nivolumab activity in term of ORR, DOR, mPFS, 
and mOS. In particular, higher ORRs were observed when PD-L1 
was expressed ranging from 31 to 37% respect to 18% in overall 
population and 9% in PD-L1-negative patients. Median DOR 
was longer with nivolumab than with docetaxel across different 
PD-L1 expression levels (16 vs. 5.6  months). Among PD-L1-
negative patients responsive to nivolumab, the mDOR was higher 
respect to docetaxel (18.3 vs. 5.6 months). This result highlights 
how PD-L1 alone is a defective predictive biomarker.
A further sub-analysis in strong PD-L1-positive tumors (i.e., 
>50%) has confirmed the axiom “more PD-L1 expression on 
tumor and more nivolumab clinical activity.” There are many 
reasons to consider PD-L1 expression as a weak predictive bio-
marker. First of all, the confounding role between predictivity 
and prognosis. Many studies associated PD-L1 overexpression 
with poor prognosis (39); however, prognosis depends on 
the characteristic of PD-L1 expression and on lymphocyte 
population forming tumor-infiltrating cells. In fact, CD8 T 
cells infiltrations strongly correlates with good prognosis in 
NSCLC, while high B cells and CD4 T cells seem to not impact 
on prognosis (40–42). It is possible to assume that the subtypes 
of TILs and the frequency of CD8+ T cells infiltrating tumor 
and PDL1 tumoral expression are all important to predict the 
activity of nivolumab more than PD-L1 expression alone. In 
fact, like chronic infection, in cancer antigen, persistency leads 
to T cell exhaustion with a high number of T reg and other 
immunosuppressive myeloid cells constituting TILs. In this 
situation, tumor PD-L1 expression is not enough to predict the 
activity of nivolumab on the contrary in TILs rich in T cells 
CD8+ even with PD-L1 low expression the immune checkpoint 
inhibitor could stimulate the awakening of competent immune 
system.
Some elegant models seem to corroborate this hypothesis: 
the frequency of CD8+ T cells may be associated with better 
clinical response to immune checkpoint blockade (43, 44), while 
an immunosuppressive protumoral microenvironment defines 
intrinsic resistance to anti-PD1 therapy (45). Moreover, myeloid-
derived suppressor cells (MDSCs) are recently emerged since 
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they produce many factors stimulating angiogenesis and immu-
nosuppression with a reduction of viability and number of CD8+ 
T cells in TILs (46).
Furthermore, MDSCs accumulate in tumor and blood of 
NSCLC patients, and they are associated with poor prognosis 
(47, 48). Their quantity reflects a higher number of neutrophil 
count and a simple and easy calculation of neutrophil to lympho-
cyte ratio could be a predictive marker of response to immuno-
therapy (49, 50).
Regarding clinical features associated with a major probability 
of response, data from a subgroup analysis showed that smoking 
habit has an important role, especially in non-squamous histol-
ogy. Ever smoker has a great possibility to have a clinical benefit 
from nivolumab as demonstrated from CheckMate 057 study 
(23). This aspect is related to a higher rate of non-synonimous 
load mutation due to genetic instability of tumors occurring 
more in smokers than in never-smokers patients. These neoan-
tigens may elicit an immune response in particular when their 
expression is represented in most tumor cells generating the 
theory that a clonal mutation has a better possibility to gener-
ate a neoantigen recognized by immune system rather than a 
subclonal expression (51).
Tumors with low mutational burden seem to benefit less from 
nivolumab according to a subgroup analysis from CheckMate 
057. Moreover, it was shown that EGFR-mutated tumors and 
never-smokers patients had a similar benefit if treated with 
docetaxel or nivolumab.
The expression of PD-L1 in tumors harboring EGFR mutations 
or ALK translocations is generally high; however, no reliable data 
and final conclusions can be drawn from literature data (52, 53).
Recently, in a larger cohort of EGFR/ALK-positive patients, 
the lack of expression of PD-L1 and the absence of CD8+ T cells 
in TILs surrounding these tumors were seen. This aspect could 
classify oncogenic driven tumors as non-inflamed tumors, sug-
gesting a scarce probability to induce an immune awakening and 
a low activity from immune checkpoint inhibitor agents (54).
The mutational load combined with PD-L1 expression and 
the analysis of lymphocyte subpopulation of TILs may represent 
a sort of signature of prediction of response to nivolumab. 
However, no standard cutoff are available, and there are still many 
methodological issues regarding the definition of “high” vs. “low” 
mutational rate tumors.
Nivolumab demonstrates higher efficacy than docetaxel 
in second line irrespective to PD-L1 expression and in non-
squamous patients this benefit increases with the expression of 
PD-L1. However, the mDOR of nivolumab and its better safety 
profile renders this drug a reasonable choice even in PDL1-
negative patients. This finding led the FDA and EMA approval of 
nivolumab for all-comers patients and several guidelines do not 
recommend PDL1 testing.
The issue of a specific predictive biomarker is an important 
challenge since nivolumab is not a treatment that fits for all 
patients for several reasons.
First of all the safety: in a post hoc analysis from CheckMate 
057, a higher risk of death emerged in the first 3  months of 
treatment with nivolumab respect to docetaxel in particular in 
poor prognosis patients, especially those with worse ECOG PS 
and heavy disease burden (55). This aspect is partially explained 
by a delayed pattern of response of nivolumab, but other charac-
teristics may contribute to contraindicate the use of nivolumab 
instead of chemotherapy. Second, the sustainability of nivolumab 
therapy for all patients, in particular in non-squamous histology, 
across countries.
Some authority regulation agencies like UK National Institute 
for Health and Care Excellence and Canadian Agency for Drugs 
and Technologies in Health rejected the use of nivolumab merely 
due to costs defining this drug as non-cost-effective (56, 57).
Recently, the Swiss Health System conducted a study in order 
to investigate the cost-efficacy of nivolumab compared with doc-
etaxel. A way to consider this drug effective and sustainable is to 
select patients with non-squamous histology and testing PD-L1 
(cutoff >10%). However, an acceptable ICER threshold of CHF 
100,000/QALY is reached only reducing the price of the drug or 
the dosage or the duration of treatment (58).
It is probable that the absence of a predictive marker of activ-
ity will not allow nivolumab to confirm its usefulness largely 
demonstrated in many trials in a real-world population due to 
accessibility disparity across countries.
OveRCOMe THe ReSiSTANCe:  
FUTURe STRATeGieS
There are two main causes of resistance to immune checkpoint 
inhibitors: the first one is an intrinsic resistance and the second 
one is an acquired resistance. The former, excluding the mecha-
nism of pseudo-progression, is due to an immunologic ignorance 
or an adaptive immune resistance. The combination of PD-L1 
expression and TIL presence surrounding and within a tumor 
may classify carefully this situation (59).
The immune-ignorant phenotype lacks a precise strategy; 
however, the combination of chemotherapy and nivolumab could 
switch this situation toward and “immune-awakening” due to the 
delivery of neoantigens as killing effect to chemotherapy use. In 
the Phase I multicohort study, CheckMate 012 nivolumab was 
combined with PT-DC (25). In this non-pretreated cohort, the 
combination showed a good safety profile and encouraging activ-
ity in particular when nivolumab at 5 mg/kg was combined with 
the paclitaxel–carboplatin regimen leading to a 62% of 2-year OS 
rate. Data are still immature to definitely suggest the application 
of this strategy only to immune-adaptive resistance or ignorance. 
Nevertheless, it is intriguing to think about a different strategy in 
cases where the use of nivolumab alone predicts a worse clinical 
benefit.
Another approach is to combine nivolumab with the anti-
CTLA4 agent ipilimumab in order to enhance T-cell antitumor 
activity through distinct and complementary mechanisms.
Based on the sole PD-L1 expression, it could be presumed that 
in PD-L1-positive tumor nivolumab alone should be enough and 
in PD-L1-negative tumors the combination with ipilimumab 
could restore the sensitivity to nivolumab.
Several cohorts of CheckMate 012 explored the combination 
of different doses of nivolumab and ipilimumab. Recently, the 
combination of nivolumab 3 mg/kg every 2 weeks + ipilimumab 
10
Cortinovis et al. Nivolumab in Lung Cancer
Frontiers in Medicine | www.frontiersin.org December 2016 | Volume 3 | Article 67
1  mg/kg every 6 or 12  weeks demonstrated a good tolerability 
profile and promising efficacy with an ORR of 39–47% with 
mDOR not reached in first-line treatment (37). Patients with 
higher levels of PD-L1 expression had especially robust responses 
to the nivolumab/ipilimumab combination. Among patients with 
tumor PD-L1 expression levels of ≥50% treated with nivolumab 
every 2  weeks and ipilimumab Q12w, the ORR was 100% and 
the median PFS was 13.6  months. However, the nivolumab/
ipilimumab combination demonstrated efficacy across all tumor 
PD-L1 expression levels, even among patients with <1% tumor 
PD-L1 expression.
The combination of ipilimumab 1  mg/kg q6w +  nivolumab 
3  mg/kg q2w in PD-L1 unselected population is ongoing in a 
Phase III trial in first-line treatment (CheckMate 227).
In order to circumvent the intrinsic or acquired resistance, 
other strategies are under investigation. Early phase trials suggest 
an activity in particular with the combination with other inhibi-
tors or agonists of immune synapse like Abs targeting CSF1R, 
LAG3, TIM3, IDO, GITR, and OX40. Finally, the combination of 
nivolumab and radiotherapy (60) or CAR-engineered T cell ACT 
and vaccines (61) may represent a fascinating strategy to enhance 
the activity of nivolumab alone.
In EGFR-positive tumors where there is a lack of response 
of nivolumab in patients previously treated with TKIs, the 
research is currently focused on naïve EGFR TKI population. 
This approach is based on the link between the high probability 
to generate a response with EGFR TKIs in naïve population and 
the induction of upregulation of PDL1 and TILs. Nivolumab 
was studied in pretreated and in EGFR TKIs naïve population 
with promising results observed in the naïve group (62). With 
the same rationale nivolumab is currently being studied with 
crizotinib (NCT01998126) and results are largely awaited.
Another strategy to explore is the combination between 
immune-checkpoint inhibitors and antiangiogenic agents due to 
cross talk between this two systems and the possibility to influ-
ence the angiogenic power and immune-tolerance against tumor. 
However, even if the rational is strong, the huge number of factors 
regulating these two axes renders difficult to forecast the results.
In conclusion, nivolumab currently represents the gold stand-
ard for the therapy of advanced, pretreated SCC NSCLC and 
may represent, with some criticism about the role of PDL tumor 
expression, a valid option in pretreated nsq NSCLC.
The sustainability and disparity across countries lead the 
affordability of this drug a main concern for the future. Even if 
for the first time, we have observed a long and durable response 
in lung cancers using nivolumab in second line, many questions 
remain to be answered. In particular, the understanding of the 
right selection of the patient who would benefit more from the 
drug and the next step of moving toward a first-line treatment 
with nivolumab in all-comers to control cancer growth from the 
beginning.
Finally, it is crucial to understand and overcome the immu-
noresistance mechanisms in order to develop future studies not 
only trying a combination based on “in vitro” rationale but ori-
enting the discoveries of older trials in biologically based Phase 
I studies.
Nivolumab is not a “one-size fits all” treatment and the main 
risk is to deny one of the most powerful drug ever employed in 
clinical practice.
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